Personalis, Inc. (PSNL) — SEC Filings
Personalis, Inc. (PSNL) — 36 SEC filings. Latest: 8-K (Nov 28, 2025). Includes 17 8-K, 6 10-Q, 5 SC 13G/A.
View Personalis, Inc. on SEC EDGAR
Overview
Personalis, Inc. (PSNL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 28, 2025: On November 28, 2025, Personalis, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material event detailed in the provided text. The company is incorporated in Delaware and headquartered in Fremont, California.
Sentiment Summary
Across 36 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 33 neutral. The dominant filing sentiment for Personalis, Inc. is neutral.
Filing Type Overview
Personalis, Inc. (PSNL) has filed 17 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 5 SC 13G/A, 2 SC 13D/A, 1 SC 13G, 1 SC 13D with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (36)
Risk Profile
Risk Assessment: Of PSNL's 29 recent filings, 2 were flagged as high-risk, 17 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $14.495M |
| Net Income | -$21.652M |
| Cash Position | $49.973M |
| Total Assets | $242.839M |
| Total Debt | $71.424M |
Key Executives
- Dr. John D. "Jake" Glisson
- Christopher Hall
- Aaron Tachibana
- Eric Lefkofsky
- Andrew Polovin
- ERIC LEFKOFSKY
- Arif Janmohamed
- Barry Eggers
- Peter Y. Nieh
- Ravi Mhatre
- Karin Eastham
Industry Context
Personalis operates in the personalized cancer therapy and diagnostics sector, a rapidly evolving field driven by advancements in genomics and molecular biology. The competitive landscape includes other diagnostic companies, large pharmaceutical firms with in-house capabilities, and academic research institutions. Key industry trends involve the increasing adoption of precision medicine, the development of companion diagnostics, and the integration of AI and machine learning for data analysis.
Top Tags
sec-filing (10) · financial-reporting (5) · material-agreement (4) · 10-Q (4) · amendment (4) · 8-k (3) · 8-K (3) · ownership-change (3) · disclosure (2) · Biotechnology (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Commission File Number | 001-38943 | SEC identifier for Personalis, Inc. |
| IRS Employer Identification No. | 27-5411038 | Tax identification for Personalis, Inc. |
| Revenue for Q3 2025 | $14.495M | 43.7% decrease from $25.709 million in Q3 2024 |
| Net Loss for Q3 2025 | $21.652M | Compared to $39.089 million net loss in Q3 2024, influenced by Tempus Warrants |
| Revenue for Nine Months Ended Sep 30, 2025 | $52.303M | 22.9% decrease from $67.814 million in the prior year period |
| Net Loss for Nine Months Ended Sep 30, 2025 | $57.458M | Slight improvement from $64.859 million in the prior year period |
| Accumulated Deficit | $607.448M | As of September 30, 2025, indicating significant historical losses |
| Cash and Cash Equivalents | $49.973M | As of September 30, 2025, down from $91.415 million at December 31, 2024 |
| Accounts Receivable, net | $14.376M | As of September 30, 2025, up from $8.140 million at December 31, 2024 |
| Common Stock Outstanding | 88,804,348 | As of October 28, 2025 |
| Net Loss | $28.3M | Slightly improved from $29.1M in Q2 2024, but still a significant loss. |
| Revenue | $16.5M | Decreased from $17.2M in Q2 2024, indicating declining sales. |
| R&D Expenses | $14.1M | Increased from $13.5M in Q2 2024, reflecting ongoing investment. |
| SG&A Expenses | $15.5M | Decreased from $16.8M in Q2 2024, showing some cost management. |
| Reporting Period End Date | 2025-03-31 | Indicates the end of the financial quarter being reported. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Personalis, Inc. (PSNL)?
Personalis, Inc. has 36 recent SEC filings from Jan 2024 to Nov 2025, including 17 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PSNL filings?
Across 36 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 33 neutral. The dominant sentiment is neutral.
Where can I find Personalis, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Personalis, Inc. (PSNL) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Personalis, Inc.?
Key financial highlights from Personalis, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PSNL?
The investment thesis for PSNL includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Personalis, Inc.?
Key executives identified across Personalis, Inc.'s filings include Dr. John D. "Jake" Glisson, Christopher Hall, Aaron Tachibana, Eric Lefkofsky, Andrew Polovin and 6 others.
What are the main risk factors for Personalis, Inc. stock?
Of PSNL's 29 assessed filings, 2 were flagged high-risk, 17 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Personalis, Inc.?
Forward guidance and predictions for Personalis, Inc. are extracted from SEC filings as they are enriched.